Study drug for HER2-positive solid tumors, with dose changes
Part of Cancer, Digestive system, Skin clinical trials.
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be HER2-positive based on pathology (lab testing).
- You must be able to provide a tumor tissue sample for testing.
- For the expansion part, you must have at least one measurable visible tumor spot on scans.
- You must not have uncontrolled spread to the brain or spinal cord compression.
- You must not have certain major heart or lung problems (like uncontrolled heart failure or interstitial lung disease).
- You must not have HIV or active hepatitis B or hepatitis C infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
This trial tests a new drug, YH32364, for people with advanced solid tumors that have high levels of EGFR protein. It looks at whether the drug can help when standard treatments have stopped working.
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.
Hear when a new HER2 Positive Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.